Abstract. Previous studies have revealed that elevated expression of high mobility group A2 (HMGA2) is closely associated with the occurrence of pituitary adenomas (PAs). The expression of microRNA (miR)-16 is deregulated in PA tissues. Bioinformatics analysis has demonstrated that there is a complementary region between seed region of miR-16 and 3'-untranslated region (3'-UTR) of HMGA2 gene. In the present study, it was investigated whether miR-16 may regulate the expression of HMGA2 and whether it is involved in the pathogenesis of PAs. A total of 52 patients with PAs were recruited. Normal brain tissues obtained from 12 patients with traumatic brain injury were used as controls. The association between miR-16 and HMGA2 was validated using dual-luciferase reporter gene assay. HP75 cells were cultured in vitro and divided into the following groups: miR control, miR-16 mimic, small interfering RNA (si)-negative control, si-HMGA2 and miR-16 mimic+si-HMGA2 groups. The expression of miR-16 and HMGA2 in HP75 cells was determined using qRT-PCR and western blot. Cell proliferation was detected using the Cell Counting Kit-8 assay and apoptosis was detected using the TdT-UTP nick end labeling assay. Compared with normal pituitary tissues, the expression of miR-16 in PA tissues was significantly decreased, while the mRNA and protein levels of HMGA2 were significantly increased. miR-16 targeted the 3'-UTR of HMGA2 gene and regulated the expression of HMGA2. Transfection with siRNAs targeting HMGA2 and/or miR-16 mimics inhibited the expression of HMGA2 and the proliferative ability of HP75 cells, whereas it increased apoptosis of HP75 cells. The downregulation of miR-16 and upregulation of HMGA2 were involved in the pathogenesis of PAs. Thus, it is hypothesized that miR-16 inhibited the proliferation and promoted apoptosis of HP75 cells by inhibiting HMGA2 expression.
Introduction
Pituitary adenomas (PAs) are monoclonal tumors that originate from the anterior and posterior lobes of the pituitary gland and residual cells of the cranial pharyngeal epithelium (1) . PA is a common intracranial tumor and accounts for ~15-20% of intracranial tumors, and its incidence ranks third among intracranial tumors and second among gliomas and meningiomas (2) . High mobility group A2 (HMGA2) is a member of the HMGA family and a non-histone protein.
HMGA2 is named after the high migration ability of HMGA2 on polyacrylamide gel electrophoresis (3) . HMGA2 is a chromatin remodeling factor that contains AT-hook basic domains, which assign them the ability to bind the DNA minor groove of AT-rich DNA sequences (4) . By changing the chromatin architecture and assembling transcriptional complexes on chromatin, HMGA2 may activate or impair the activity of transcriptional enhancers in various genes indirectly (5) . In addition to serving as a transcriptional co-regulator, HMGA2 may also directly regulate the transcription activation and expression of various genes (6) . It has been demonstrated that HMGA2 regulates various biological processes, including proliferation and cell cycle. Additionally, increased expression of HMGA2 is associated with the occurrence of various tumors, including prostate (7), colorectal (3), lung (4) and breast cancer (8) , and serves an important function in the occurrence, progression and metastasis. Previous studies have revealed that increased expression of HMGA2 is associated with the occurrence of PA and prognosis, and the survival time of patients with PA (9) (10) (11) . microRNA (miRNA) is an endogenous non-coding single-stranded RNA of 21-25 nucleotides in length, which may regulate the expression of target genes by inhibiting the translation or degradation of mRNAs (12 16 patients with neurotrauma were collected during surgery and were used as controls. Among these, 9 patients were males and 7 patients were females. The average age of patients was 38.1 years (range, 33-57 years). All patients provided written informed consent and the study was approved by the Ethics Committee of Mudanjiang Forestry Hospital.
Cell culture. The human PA cell line HP75 was cultured in DMEM supplemented with 10% horse serum, 5% fetal bovine serum and 1% streptomycin, and cells were incubated at 37˚C in a humidified atmosphere containing 5% CO 2 . The culture medium was changed every 3 days. When cells reached 60-80% confluence, cells were used for subsequent experiments.
Dual-luciferase reporter assay. The HEK293 cell line genome was used as a template to amplify the full-length 3'-UTR fragment of the HMGA2 gene, cloned into the luciferase reporter vector pGL-3M and transformed into DH5α Escherichia coli competent cells. The positive clones were screened by colony PCR. Following sequencing, the positive clones were used for subsequent experiments. The HEK293 cell line was co-transfected with pGL3-HMGA2-3'-UTR (400 ng), miR-16 mimic/miR-control (25 nmol) and pRL-TK (25 ng) using Opti-MEM and Lipofectamine 2000. Luciferase assays were performed 48 h after transfection, The activity of firefly luciferase was measured and normalized to the corresponding Renilla luciferase activity.
Cell transfection. The sequences of siRNAs used in the present study were as follows: si-HMGA2, 5'-CAG CCU GAA UAA CUU GAA CTT-3' (sense) and 5'-GUU CAA GUU AUU CAG GCU GTT-3 (anti-sense); si-negative control (NC), 5'-UUC UCC GAA CGU GUC ACG UTT-3' (sense) and 5'-ACG UGA CAC GUU CGG AGA ATT-3' (anti-sense). HP75 cells were divided into the following groups: miR-control (scramble), miR-16 mimic, si-NC transfection group, si-HMGA2 group and miR-16 mimic+si-HMGA2 groups. Lipofectamine ® 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) was used for transfection, according the manufacturer's protocol. Briefly, HP75 cells were cultured in 100 mm dish at a density of 1.5-2x10 5 /ml, Following cultivation for 24 h, the cells were transfected with 100 nmol/l miRNAs using Lipofectamine 2000. Cell were cultured for 72 h before subsequent experiments.
Bioinformatics analysis. The potential direct common target genes of miR-16 were predicted using miRNA databases, including TargetScan Human 7.2 (16), miRanda (17) , and miRDB (18) . Intersecting the results of these three databases demonstrated that the HMGA2 gene was a prediction target gene.
Reverse transcription quantitative (RT-q)PCR. Total RNA was isolated from cells using TRIzol reagent. RNA was reverse-transcribed into cDNA using PrimeScript™ RT Reagent kit, according to the manufacturer's protocol. qPCR was performed using Bio-Rad CFX96 quantitative PCR system and SYBR, according to the manufacturer's protocol. The following primers were used: miR-16, 5'-AAC CCG UAG AUC UUG GAU CCU G-3' (forward) and 5'-CAA GAU CAU CUA CGG UUU GGGU-3' (reverse); U6, 5'-ATT GGA ACG ATA CAG AGA AGA TT-3' (forward) and 5'-GGA ACG CTT CAC GAA TTT G-3' (reverse); HMGA2, 5'-ACC CAG GGG AAG ACC CAA A-3' (forward) and 5'-CCT CTT GGC CGT TTT TCT CCA-3' (reverse); β-actin, 5'-GAA CCC TAA GGC CAA C-3' (forward) and 5'-TGT CAC GCA CGA TTT CC-3' (reverse). PCR was conducted as follows: Initial denaturation at 95˚C for 5 min, followed by 40 cycles of denaturation at 95˚C for 15 sec and annealing at 60˚C for 30 sec. All the samples were assessed by relative quantification (2 -ΔΔCq method) (19) .
Western blot analysis. Cells were lysed using radioimmunoprecipitation assay buffer and centrifuged at 10,000 x g for 10 min. Proteins (40 µg) were separated by SDS-PAGE (10% gels) and then transferred onto polyvinylidene fluoride membranes. The membranes were blocked with 5% non-fat milk for 60 min, followed by incubation with primary antibodies against HMGA2 (dilution, 1:500) and histone H3.1 (dilution, 1:1,000, serving as loading control) overnight at 4˚C. Membranes were then washed with 0.1% Tween-20 in PBS (PBST) three times. Membranes were then incubated with horseradish peroxidase-conjugated secondary antibody (dilution, 1:5,000) for 60 min at room temperature and then washed with PBST three times. Immunoreactive bands were visualized by an ECL Western Blotting Substrate kit. X-ray film was used to analyze the image and intensity of bands via ImageJ software (version 1.51b; National Institutes of Health, Bethesda, MA, USA).
CCK-8 assay. Cells were seeded in 96-well cell plates at a density of 1x10 4 cells/well for 24 h. Cells were cultured for additional 24, 48, 72 and 96 h at 37˚C in a humidified atmosphere containing 5% CO 2 . Then, CCK-8 reagent (10 µl) was added to each well and cells were cultured for 4 h at 37˚C in a humidified atmosphere containing 5% CO 2 . The absorbance values were read at 450 nm wavelength using a microplate reader.
TUNEL assay. Cells were washed with PBS and fixed with 4% paraformaldehyde for 60 min. PBS containing 0.1% Triton X-100 was added and cells were incubated on ice for 2 min and washed twice with PBS. Then, 50 µl of TUNEL solution was added and cells incubated for 60 min at 37˚C in dark, washed twice with PBS. Antifade mounting medium were added onto the cells and the fluorescein isothiocyanate-labeled TUNEL-positive cells were imaged under a fluorescent microscope. The cells with green fluorescence were defined as apoptotic cells. A total of 5 fields of each sample were observed.
Statistical analysis. Data were analyzed using SPSS software (version 18.0; SPSS, Inc., Chicago, IL, USA). Data are expressed as the mean ± standard deviation. Results were analyzed using Student's t-test when only 2 groups were compared. One-way analysis of variance followed by Bonferroni post hoc test was used to examine differences between groups. P<0.05 was considered to indicate a statistically significant difference.
Results

Decreased expression of miR-16 decreased and increased expression of HMGA2 in PA tissues.
RT-qPCR analysis demonstrated that the expression of miR-16 was significantly decreased whereas the expression of HMGA2 mRNA was significantly increased in patients with PAs compared with that in normal pituitary tissues (Fig. 1A) . Western blot analysis indicated that the protein expression of HMGA2 was increased in patients with PAs compared with that in normal pituitary tissues (Fig. 1B) . These results suggested that the decreased expression of miR-16 and increased expression of HMGA2 may be associated with the development of PA. Fig. 2A) . Dual-luciferase reporter assay demonstrated that miR-16 mimic significantly decreased the relative luciferase activity in the wild-type but not mutant constructs (Fig. 2B) , suggesting that miR-16 may target the 3'-UTR region of HMGA2 mRNA and regulate the expression of HMGA2. Additionally, the introduction of miR-16 mimic in HP75 cells led to decrease in gene and protein expression levels of HMGA2, thus confirming that miR-16 may regulate the expression of HMGA2 (Fig. 2C and D) .
Regulation of HMGA2 by miR-16. Bioinformatics analysis revealed that there is a complementary region between seed region of miR-16 and 3'-UTR of HMGA2 gene (
Overexpression of miR-16 promotes apoptosis and inhibits proliferation of HP75 cells. Transfection with miR-16 mimic
and/or si-HMGA2 downregulated the gene and protein expression levels of HMGA2 in HP75 cells (Fig. 3A and B) . Cell proliferation was assessed using a CCK-8 assay. The results demonstrated that transfection with miR-16 and/or si-HMGA2 significantly decreased the proliferation of HP75 cells after 24, 48, 72 and 96 h (Fig. 3C) . Additionally, apoptosis of HP75 cells was assessed using TUNEL assay. The results demonstrated that transfection with miR-16 and/or si-HMGA2 increased the number of apoptotic cells (Fig. 3D) .
Discussion
PA may lead to a series of endocrine symptoms, including acromegaly, decreased sexual function, headache, vision loss, visual field defect, hypothalamic syndrome, cerebrospinal fluid rhinorrhea and other symptoms of adjacent local tissue compression. Invasive PAs (IPAs) account for ~30% of PAs and are large tumors with infiltration of adjacent tissue. Patients with IPAs exhibit an increased postoperative recurrence rate of 50% and poor prognosis (20) . Therefore, future studies investigating the underlying molecular mechanisms are required for the diagnosis and treatment of PA.
HMGA2 is a non-histone chromatin protein that is involved in the regulation of chromatin. HMGA2 is involved in biological processes, including cell proliferation, differentiation, cell cycle and migration. Under physiologic conditions, HMGA2 is not expressed or minimally expressed in normal tissues. Abnormal expression of HMGA2 is detected in various types of cancer, including prostate (7), colorectal (3), lung (4) and breast cancer (8) . Increased expression of HMGA2 is associated with the occurrence, progression and poor prognosis of cancer. Shi et al (7) revealed that HMGA2 may be involved in the occurrence of prostate cancer by regulating cell proliferation, apoptosis, epithelial mesenchymal transition and invasion. Wu et al (21) demonstrated that upregulation of HMGA2 may be used as a biomarker of breast cancer progression and poor prognosis. Borrmann et al (22) reported that HMGA2 negatively regulated the activity of the Nucleotide excision repair cross complementing gene 1 (ERCC1) gene promoter. Additionally, HMGA2 inhibited the nucleotide excision repair pathway. Thus, HMGA2 may be involved in the occurrence of tumor by regulating DNA damage and repair. Previous studies (9) (10) (11) have demonstrated that elevated expression of HMGA2 may be associated with the occurrence of PA, the survival and prognosis of patients with PA. Previous studies (13) (14) (15) revealed that the expression of miR-16 was deregulated in PA tissues. Bioinformatics analysis indicated there is a complementary region between seed region of miR-16 and 3'-UTR of HMGA2 gene. In the present study, it was investigated whether miR-16 may regulate the expression of HMGA2 and whether it is involved in the pathogenesis of PAs.
The results of present study demonstrated that the expression level of miR-16 was decreased, whereas the expression level of HMGA2 was increased in PA tissues compared with normal pituitary tissues. These results suggest that the (10) demonstrated that the expression level of HMGA2 in tissues from patients with growth hormone-secreting PAs was significantly increased compared with that in normal pituitary glands. Oruckaptan et al (20) revealed that HMGA2-transgenic mice have an increased incidence of PA compared with normal wild-type mice. Fedele et al (11) demonstrated that overexpression of HMGA2 may lead to the development of prolactin or growth hormone adenomas in 85% of transgenic mice within 6 months. In the present study, it was demonstrated that the expression level of HMGA2 in tumor tissues from patients with PA was significantly increased compared with that in normal pituitary tissues, thus confirming the results from a previous study (10) . Amaral et al (13) demonstrated the expression level of miR-16 in tumor tissues from patients with PA was significantly decreased compared with normal tissues. Bottoni et al (14) revealed that the expression level of miR-16 was significantly decreased in PA tissues compared with normal pituitary tissues. Renjie and Haiqian (15) demonstrated that the expression level of miR-16 was significantly decreased in PA cell lines compared with that in control. Additionally, the expression level of miR-16 was significantly increased in patients with IPA compared with that in patients with non-invasive PAs (15) , suggesting that decreased expression of miR-16 may be involved in the pathogenesis of PA. The present study demonstrated that the expression level of miR-16 in PA tissues was significantly decreased compared with that in normal pituitary tissues, thus confirming the results from previous studies (13, 14) . The dual-luciferase reporter assay demonstrated that transfection of miR-16 mimic decreased the relative luciferase activity, and the protein and gene expression level of HMGA2 in HP75 cells, suggesting that miR-16 may target HMGA2. Additionally, upregulation of miR-16 or transfection of si-HMGA2 significantly decreased the expression level of HMGA2 in HP75 cells. Additionally, transfection with miR-16 and/or si-HMGA2 significantly decreased the proliferation but increased apoptosis (24) confirmed that HMGA2 binds to the promoter region of the G2/mitotic-specific cyclin-B2 (CCNB2) gene to upregulate the expression of CCNB2 and promote cell mitosis and proliferation, thus serving a function in the occurrence of PAs. Additionally, the association between HMGA2 and apoptosis has been demonstrated by previous studies (25, 26) . In the present study, si-HMGA2 interference and miR-16 overexpression inhibited cell proliferation and promoted apoptosis by inhibiting the expression of HMGA2, which in turn may regulate cell cycle, mitosis proliferation and apoptosis. The molecular mechanism underlying the function of HMGA2 in PAs needs to be further identified. In summary, the results of the present study demonstrated that the expression of miR-16 was decreased and the expression of HMGA2 was increased in PA tissues. miR-16 may inhibit the proliferation of HP75 cells and promote apoptosis by inhibiting the expression of HMGA2.
